<DOC>
	<DOCNO>NCT00600587</DOCNO>
	<brief_summary>The purpose study evaluate value induction Erlotinib therapy thoracotomy radiotherapy ⅢA-N2 ( confirm mediastinoscopy PET ) non-small cell lung cancer ( NSCLC ) select epidermal growth factor receptor ( EGFR ) gene analysis initial explore new treatment strategy ⅢA-N2 NSCLC .</brief_summary>
	<brief_title>Induction Erlotinib Therapy Stage III A ( N2 ) Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Stage IIIA non-small-cell lung cancer ( NSCLC ) see relatively heterogeneous group patient ipsilateral mediastinal ( N2 ) lymph node involvement . The relative role different treatment modality clear . Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKIs ) may result dramatic response patient pulmonary adenocarcinoma carry EGFR activate mutation . In case report , efficacy perioperative EGFR-TKI therapy patient locally advance NSCLC harbor EGFR gene mutation satisfactory . Although prospective data support use EGFR-TKIs induction therapy stage IIIA-N2 NSCLC , low toxicity profile possibility rapid tumor response suggest prospective trial require . Therefore , study evaluate value induction erlotinib therapy IIIA-N2 NSCLC select EGFR gene analysis explore new treatment strategy subset . Erlotinib specifically target EGFR TK domain , highly express occasionally mutate various form cancer . It bind reversible fashion adenosine triphosphate ( ATP ) bind site receptor .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Written inform consent Histological cytological document Resectable NSCLC stage IIIAN2 confirm mediastinoscopy PET Naive therapy NSCLC Candidates tolerate induction therapy thoracotomy ECOG performance status 02 , adequate haematological Hepatic renal function qualify lung function Enough tissue sample perform gene analysis Small cell lung cancer Pregnant breastfeed woman Any unstable systemic disease Patients exposure investigational drug therapy concurrent anticancer therapy outside trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Genes , erbB-1</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
</DOC>